Testosterone Replacement Therapy

Introduction to Testosterone Replacement Therapy

• Testosterone replacement therapy (TRT) is a treatment for low testosterone levels, with the goal of alleviating symptoms and improving quality of life, as recommended by the American Urological Association 1, 2, 3, 4, 5
• Patients on TRT should be informed about the potential benefits and risks, including the potential for decreased fertility, as recommended by the American Society for Reproductive Medicine 3, 4, 5, 6

Monitoring and Follow-up

• Patients on TRT should have regular monitoring of testosterone levels, hematocrit/hemoglobin, and PSA with digital rectal examination at baseline, 3-6 months for the first year, and annually thereafter to prevent serious complications, as recommended by the American Urological Association 6
• Initial follow-up should occur 1-2 months after starting TRT to assess efficacy of treatment and consider dose adjustment if response is suboptimal, with a target total testosterone level of 450-600 ng/dL 6, 7
• Regular monitoring should include assessment of PSA, digital rectal examination, and hematocrit levels, with a critical threshold of >54% for hematocrit, as recommended by the American Urological Association 6
• For patients on injectable testosterone, monitoring should include assessment of fluctuations in testosterone levels, with peaks 2-5 days after injection and return to baseline by 10-14 days, as reported by the New England Journal of Medicine 6

Laboratory Tests and Timing of Measurement

• Hematocrit levels should be monitored, with a critical threshold of >54%, and treatment should be temporarily withheld, dosage reduced, or phlebotomy considered if elevated, as recommended by the American Urological Association 6
• Liver function tests are not necessary for routine monitoring of intramuscular injections and transdermal preparations, as reported by the New England Journal of Medicine 6
• Testosterone levels should be measured midway between injections for injectable testosterone, targeting 500-600 ng/dL, and at any time for transdermal preparations, as recommended by the Endocrine Society 7
• Total testosterone concentration should be measured between 8-10 AM to account for diurnal variation, as recommended by the Endocrine Society 7
• The following monitoring parameters are recommended:

4, 5

Lifestyle Changes and Dietary Recommendations

• A Mediterranean diet pattern, emphasizing fruits, vegetables, beans, legumes, whole grains, nuts, fish, poultry, lean red meat, healthy fats, and moderate alcohol consumption, is recommended to increase testosterone levels in men with low testosterone, as reported by the Mayo Clinic Proceedings 2
• Lifestyle changes such as weight loss, regular physical activity, adequate sleep, stress reduction techniques, healthy diet, moderate alcohol consumption, and smoking cessation can increase testosterone levels and improve symptoms, particularly in men with metabolic disorders or obesity, as recommended by the European Urology association 8
• Regular physical activity can reduce the risk of type 2 diabetes and coronary heart disease by 30-50%, as reported by the Mayo Clinic Proceedings 2

Medications and Interactions

• Opioids and opiates, particularly with increased dosage and prolonged use of methadone, can lead to hypogonadism in patients, as supported by the Endocrine Society 9
• Glucocorticoids (corticosteroids) can indirectly affect testosterone levels by causing weight gain, according to the American College of Physicians 9
• Antipsychotics, especially second-generation antipsychotics like olanzapine, quetiapine, and risperidone, can cause hypogonadism through direct hormonal effects and indirect effects through weight gain, as noted by the European Association of Urology 9
• Alternatives to antipsychotics with less impact on testosterone levels include ziprasidone and aripiprazole, recommended by the American Psychiatric Association 9

Diagnosis and Treatment

• Total testosterone concentration <300 ng/dL is generally considered low, and the free testosterone index (total testosterone/SHBG ratio) < 0.3 indicates hypogonadism, as suggested by the European Association of Urology 7, 1
• Measuring sex hormone-binding globulin (SHBG) and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels is essential to determine the type of hypogonadism, as recommended by the Endocrine Society 1, 8
• Injectable testosterone, transdermal formulations, and testosterone pellets are recommended treatment options, each with their advantages and disadvantages, as reported by the New England Journal of Medicine, and gonadotropins (hCG, FSH) may be used when fertility preservation is needed, as suggested by the American Urological Association 6, 10
• The weight of evidence suggests TRT is not associated with increased cardiovascular risk in most men, but caution is advised in those with existing cardiovascular disease, with a moderate strength of evidence, as indicated by the American College of Physicians 3, 4, 5, 6